Back to Directory

Katie McCarthy

Email

kmccarthy@fhi360.org

Phone

(919) 321-3326

Institution

FHI 360

Title

Clinical Research Manager

Address

FHI 360
359 Blackwell St.
Suite 200
Durham, NC 27701
United States of America

Request an Update

Affiliated Studies

IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV

DAIDS Number

39052

Research Area

Therapeutics

Study Status

Pending

IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis

DAIDS Number

38754

Research Area

Tuberculosis

Study Status

Enrolling

IMPAACT 2010: VESTED

DAIDS Number

30129

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV

DAIDS Number

20721

Research Area

Tuberculosis

Study Status

Closed to Accrual

1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival)

DAIDS Number

10779

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

Show All